| Sep 25 |
Emergent Bio gains after confirming $400M orders for 2024/25
|
| Sep 25 |
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
|
| Sep 24 |
Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains
|
| Sep 24 |
U.S. to donate 1M mpox shots to address outbreak in Africa: report
|
| Sep 13 |
Emergent Bio to pay $40M to settle class action lawsuit
|
| Sep 13 |
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
|
| Sep 12 |
Morocco reports first mpox case amid ongoing global outbreak
|
| Sep 12 |
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
|
| Sep 12 |
BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc.
|
| Sep 5 |
Singapore announces quarantine measures for close contacts of mpox infected patients
|
